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Abstract
Background. Ménière’s Disease (MD) often presents with aural fullness, for reasons that
are currently not well understood. Insertion of transtympanic ventilation tubes (VTs) has
been historically used for the management of this symptom, though the nature and
mechanism of effectiveness is unclear. Objectives. To give an overview of the data
available on the effects of VT insertion on aural fullness in MD. Methods. The databases
PubMed, EMBASE, Medline, SCOPUS, Web of Science, CENTRAL and Google Scholar were
searched to identify relevant records. Records were subsequently analysed and data
extracted. Results. Only two studies directly measured the effect of VT insertion on aural
fullness, while three others measured it as a placebo to another treatment. Considerable
heterogeneity was found among the studies, including conflicting conclusions.
Conclusions. There is a paucity of evidence investigating the effect of grommet insertion
on aural fullness in MD. This work directs future research into this topic.
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Introduction
Ménière’s Disease (MD) is a condition characterised by attacks of vertigo
which are accompanied by tinnitus, low-frequency hearing loss and the
perception of aural fullness1. It is thought that symptoms of MD can be
attributed to endolymphatic hydrops – pathological excess of endolymph
in the scala media of the inner ear, resulting in distension of membranous
structures such as Reissner’s membrane and the semicircular canals2, 3. In
comparison to other symptoms, aural fullness is considered a lesser
complaint of MD as it is usually less debilitating than the vertigo, tinnitus
and hearing loss4. Although the exact mechanism of how aural fullness
occurs is unclear, it has been postulated that it could be due to associated
degeneration in the trigeminal ganglion5. The recent identification of
nociceptive fibres in the mammalian cochlea may indicate an alternative
mechanism6, 7. Levo et al.4 has shown that although several conservative
methods such as salt restriction may be attempted to alleviate aural
fullness, only relaxation showed statistically significant results. This
suggests a possible psychological element to the symptom.
Studies investigating aural fullness in MD have been lacking, potentially
due to the perceived mildness of this complaint compared to the other
disease symptoms. During active MD and even in remission, the symptom
of aural fullness can be extremely troublesome in the senior experience.
This complaint is not uncommon in the ENT clinic and was the chief
complaint in almost 1.5% of patients seen in one clinic of which 23% had
an inner ear cause8. In the treatment of MD, insertion of ventilation tubes
(VT), or “grommets”, has been a popular intervention amongst UK
Otolaryngologists for decades. Smith et al.9 reported a national survey of
UK otolaryngologists and found that 8% of responders chose to insert a
VT as initial surgical management. Harcourt et al.10 also acknowledged
the intervention’s popularity in their review of Ménière’s Disease in 2014.
This practice is changing with the concept of evidence based medicine;
however it is still seen in practice today to treat MD. Historically, studies
looking at treatments for MD have included VT insertion11, 12. Whether this
is to treat the symptom of aural fullness or the disease itself is unclear.
The use of VTs is attractive as it potentially carries far fewer risks than
alternatives such as intratympanic gentamicin and endolymphatic sac
surgery13. The reasons why VTs may help alleviate endolymphatic
hydrops are not well understood14. Proposed mechanisms include
decreasing middle ear pressure which consequently reduces
endolymphatic pressures and alleviation of hypoxic inner ear
environments that lead to hydrops by introduction of oxygenated air from
the external ear15, 16. In the presence of a functioning Eustachian tube, it
is difficult to understand these hypotheses fully17. Despite being a
relatively popular surgical treatment option for the condition10, there are
no existing systematic or scoping reviews targeting the effects of VT
insertion, nor the symptom of aural fullness, on MD.
Objectives
This review aims to catalogue the data on the use of VTs on aural fullness
in Ménière’s disease. The primary objective of this paper is not to
determine whether VT insertion is effective in treating this symptom, but
to give an overview of data available in this field, regardless of the quality
of evidence, and to summarise key findings.
Methods
This review follows the 5-stage methodological framework outlined by
Arksey and O’Malley for conducting a scoping review18.
Inclusion criteria
Studies of all types published in English language journals and grey
literature were included as long as they describe how ventilation tube
insertion affects the degree of perceived aural fullness in participants with
MD.
Exclusion criteria
Exclusion criteria were the following:
1) Studies showing the effect of VTs exclusively on other MD
symptoms.
2) Studies showing the effect of VTs insertion on aural fullness
exclusively on conditions other than MD.
3) Studies that only showed how aural fullness changed after
administration of a secondary therapy to VT insertion e.g. pressure
therapy, gentamicin.
4) Studies not specifying aural fullness specifically as the symptom
being affected by VT insertion e.g. only mention how VT insertion
improved general patient functioning without specifying aural
fullness as the improved symptom.
5) Review articles synthesising existing data.
Electronic searches
The following databases were searched: PubMed, EMBASE, Medline,
SCOPUS, Web of Science, CENTRAL, OpenGrey, DART-Europe, Proquest
and Google Scholar. Search terms used: ("menier* disease" OR "menier*
syndrome" OR "endolymphatic hydrops") AND ("grommet" OR "ventilation
tube" OR “transtympanic tube” OR “transtympanic ventilation tube”) AND
("fullness" OR "pressure" OR “otalgia”). Search date 14th January 2018.
Search results were limited to only include English and human studies.
Searching other resources
The reference lists of identified studies were also screened for papers that
were not found by the electronic search. Any additional studies meeting
the criteria for this review were added to the results.
Selection process
Two authors independently scanned the search hits based on titles,
keywords and available abstracts. The titles and abstracts of the search
results were screened for relevant articles to be included in the review
based on the inclusion and exclusion criteria. The full texts of the
remaining articles were then acquired and screened. In cases where there
was uncertainty on the relevance of a record based on its abstract, the
full text was screened. Discrepancies about which articles to include were
discussed and subsequently resolved, by third party involvement if
necessary.
Data Analysis
The following data, if available, was extracted from studies meeting the
criteria for this review:
1) Aims and methods of the study.
2) Details of patients involved (e.g. age, gender, number).
3) The type of disease being treated i.e. whether Ménière’s Disease or
Syndrome, laterality etc.
4) Method of aural fullness assessment.
5) Time elapsed after VT insertion until aural fullness was measured.
6) Changes in aural fullness, both qualitative and quantitative.
7) Discussion on the safety of the intervention.
Results
Search results
A total of 803 search hits were acquired through the electronic search
strategy previously described. After duplicate removal, 559 results
remained for scrutiny by two authors under the set criteria (Figure 1).
Another study was found through searching references of relevant papers.
Ten records remained after exclusion of records based on title and
abstract. Four studies meeting the criteria based on their full articles were
found via the electronic search, which were Dayal19, Densert et al.20,
Odkvist et al.21 and Postema et al.22. An additional study by Lall23, which
was identified from references of papers, also met the criteria and was
included. Table 1 summarises the details of these studies.
Study aims and characteristics
A detailed analysis of the quality of the studies involved is beyond the
scope of this review, as its aim is not to determine the efficacy of this
treatment. However, it is notable that only two of the included studies
directly measured the effect of VT insertion on aural fullness19, 23 while the
other studies included it based on their use of the VT as a placebo to
another therapy20-22. For example, in the study by Odkvist et al.21, the
effect of VT insertion on aural fullness could be inferred from the placebo
treatment as a VT was inserted but the placebo device did not deliver any
pressure pulses. Therefore, any changes in aural fullness could be
attributed to VT insertion alone. Lall23 compiled data received from
questionnaires sent to members of the British Association of
Otolaryngologists at the time about the effect of VT insertion on the
symptoms of their patients with MD. The case series by Dayal19 directly
observed the effects of VT insertion on the symptoms of patients with MD.
The studies by Odkvist et al.21, Densert et al.20 and Postema et al.22 were
randomised placebo-controlled trials, although none directly measured the
effects of VT insertion on MD symptoms.
Patient demographics
In studies where patient ages were specified, all were adults (20 – 65
years old)19-22. Only Dayal19 specified the gender of participants and in
this case, all 7 patients in this study were male. Table 2 shows the
number of participants in each study. Although Lall’s23 study had the most
number of patients (147 patients), this was a conglomerate of results that
the author acquired from a questionnaire sent out to multiple surgeons,
and the specific age, gender and disease type of these patients are
unknown. Dayal19 and Postema et al.22 were the only to measure aural
fullness in all patients receiving VTs, although data was lost for two
patients in the latter study. Additionally, it is only clear in Dayal’s19 study
that all of his patients had aural fullness prior to intervention. In the
others, it is unknown how many of the patients receiving intervention had
complained of aural fullness prior, nor the symptom severity.
Diagnostic criteria for Ménière’s Disease
The vast majority of patients were defined as having “Ménière’s Disease”,
with only 15 patients in the study by Lall23 being defined with “Ménière’s
Syndrome.” Two studies diagnosed MD based on the criteria set out by
the 1995 Academy of Otolaryngology-Head and Neck Surgery (AAOHNS)
20, 22. This is also likely the case for the study by Odkvist et al.21, as they
described their patients all having “definite Ménière’s Disease”. Specific
diagnostic criteria for patient recruitment are not stated in the other two
papers. The patients in the study by Densert et al.20 and Postema et al.22
all had unilateral MD, while disease laterality was unspecified in the other
three studies.
Measurement of aural fullness
Visual analogue scales were used in the studies by Densert et al.20 and
Odkvist et al.21. The exact nature of both scales is unknown, although
Odkvist et al.21 stated that their scale measured symptom frequency and
intensity. Postema et al.22 asked participants to use a 0-3 scale to rate
their symptom severity, with 0 equating to no symptoms and 3 being
severe. Lall23 acquired data on how aural fullness changed after VT
insertion from several surgeons using a questionnaire. Although the exact
nature of this questionnaire is unknown, the changes in symptoms were
presented as either “relieved”, “no change” or “incomplete data.” Changes
in the other MD symptoms were also presented in this paper and options
for these also included “worsened”, “complete lasting relief”, “slight
lasting relief” and “temporary relief”. It is unknown if these options were
also present to describe the change in aural fullness. Additionally, it is not
stated how any of the surgeons responding to the questionnaire
measured aural fullness. Dayal19 did not specify how aural fullness was
assessed after the operation, although their results were presented in the
paper.
Time elapsed until aural fullness measurement post-VT insertion
Odkvist et al.21 made a clinical and audiological assessment 2 weeks after
VT insertion. At this point, patients still fulfilling the entry criteria for
having MD continued in the study. It is unstated if aural fullness
measurement was part of this clinical assessment. After a further 2
weeks, aural fullness was measured in both the active pressure treatment
and placebo group, and it is the result of this placebo group that is
considered by this review. Postema et al.22 left a 4 week waiting period
after VT insertion, and then afterwards administered gentamicin
treatment or placebo weekly for 4 following weeks. Aural fullness was
measured at each visit, and then afterwards at 6 weeks, 6 months and 1
year post-treatment initiation. Aural fullness data is only available for 1
year post-placebo therapy. Follow-up periods for participants in Lall’s 23
and Dayal’s19 studies ranged between 2-14 months and 3-12 months
respectively, although specific patient follow-up periods are unstated.
Densert et al.20 did not specify when they measured aural fullness.
Changes in aural fullness post-VT insertion
Densert et al.20 and Odkvist et al.21 both stated that their placebo, and
hence VT only, groups showed no significant changes in aural fullness
post-treatment. Specific quantitative results from their visual scales are
not presented. Postema et al.22 also showed that their placebo group’s
perceived aural fullness did not change. However, they presented their
results as histograms showing the distribution of perceived aural fullness
as stated by patients according to their numerical scale before and after
therapy. However, it is unknown how the aural fullness of each individual
patient changed, only that the overall distribution of symptom severity did
not change. Two of these patients were lost to follow-up and so data was
only available on 10 patients at 12 months. Dayal19 stated that 6 out of 7
patients experienced relief of aural fullness post-VT insertion, while 1
patient experienced no change in symptoms. However, the degree of
relief or initial symptom severity was not stated. Finally, Lall’s23 survey
showed that, of all the patients treated by the responding surgeons, 66%
showed relief of aural fullness after VT insertion and 22% showed no
change. Data was incomplete for the remaining 12%. Again, the degree of
relief and change from initial symptoms were not available for individual
patients. Additionally, it is not stated how many of these patients
experiencing symptomatic relief were classified as having either
“Ménière’s Disease” or “Ménière’s Syndrome”.
Safety of intervention
Dayal19 and Lall23 both commented on the general ease and safety of VT
insertion compared to more destructive surgical interventions, however
this is not discussed in detail. Dayal19 also stated the limitation that the
patient must be careful to not allow water to enter the ear. Lall23 stated
that twenty-eight cases experienced relapse of symptoms following VT
extrusion, though it is unclear what these symptoms are. Some of these
cases underwent another procedure for re-insertion, although the safety
implications of these were not discussed. In the same study, it is noted
that 3%, 3% and 6% of patients experienced worsened symptoms of
vertigo, deafness and tinnitus respectively, although it is not stated
whether these could be attributed at all to the intervention. The other
three studies did not comment on the safety of VT insertion. None of the
studies commented on whether the VT was inserted under local or general
anaesthetic.
Levels of evidence
The two studies by Dayal19 and Lall23 which directly address the effect of
VT insertion on aural fullness were case series (Level 4 evidence),
whereas the other three studies which used it as a placebo20-22 were RCTs
(Level 2 Evidence)24. However, as the RCTs do not measure the effect of
VT insertion on aural fullness as their primary outcome, these levels of
evidence cannot be correctly applied to these studies20-22. The case series
are a lower form of evidence due to the risk of bias by the author’s
opinions, as well as lack of confounding factor control25.
Discussion
Importance of the research question
This review has identified records that have attempted to determine the
effects of VT insertion on aural fullness in MD patients. However, despite
a wide search strategy that encompasses all study types, all patient
demographics, and that accepts VT insertion and measurement of aural
fullness as secondary aspects to the study, only five studies met the
criteria. From the outset, this indicates a gap in the literature. VT
insertion is a safe, simple procedure and it would be beneficial to the
patient if their symptoms could be controlled with this approach, prior to
more destructive interventions17, 23. It is notable that only two studies
measured the changes in aural fullness due to VT insertion as the primary
intervention and in neither of those studies was that symptom the
primary outcome19, 23. It is also noteworthy that the two studies directly
measuring the effects of VT on aural fullness were published 50 years
ago. Although considered as part of the diagnostic criteria of MD1, aural
fullness may not be considered as a main feature of the condition by
some clinicians, being overshadowed by the classic triad of vertigo,
hearing loss and tinnitus26, 27. However, aural fullness is still an important
feature of the condition as severe manifestations can significantly impact
a patient’s quality of life, leading to social isolation4. The lack of recent
studies directly measuring the effect of VT insertion on aural fullness
shows scope for an update to research on this topic.
Measuring aural fullness
Three out of the five studies measured aural fullness using a patient
subjective visual analogue scale, showing that this was the preferred way
of assessing changes in the symptom20-22. However, as two of these
studies did not specify what was included in their questionnaires, it
cannot be ascertained what should be included in such a scale to best
measure aural fullness20, 21. While Lall23 employed a different approach by
simply asking whether the symptom was relieved or not, this would not
allow measurement of the degree of symptom change. No objective
measure of aural fullness was mentioned in any of the studies, most likely
because the mechanism of development of this symptom is not
understood. Additionally, no consensus exists as to when best to measure
changes in aural fullness post-VT insertion, with follow-up measurements
ranging from 4 weeks to 14 months. Due to lack of understanding the
pathophysiology behind aural fullness development in MD, it is unknown
when best to measure the effects of VT insertion on the symptom.
However, the minimum timeframe until measurement of symptoms is 4
weeks post-VT insertion in the included studies; therefore it is unknown
whether there are any changes in aural fullness prior to this. Knowing
how quickly aural fullness is relieved, if at all, may help direct
understanding of why this symptom occurs in MD.
Efficacy of intervention
The studies included in this review have shown mixed results as to the
effects of grommet insertion on aural fullness in MD. While this review
cannot determine the effectiveness of VT insertion in MD aural fullness, it
has shown that no randomised control trial exists to answer this question.
Finally, the possibility of a placebo effect being the cause of symptomatic
improvement after grommet insertion must be considered. A placebo-
controlled trial would be needed to distinguish the true effect of VT
insertion in MD aural fullness from placebo effects28, a practice supported
by the Royal College of Surgeons29. We recognise that this may not be
feasible or required given the lack of evidence to support this treatment in
MD.
Conclusions
Although the quality of evidence was not formally appraised, this scoping
review reveals a severe lack of literature detailing the effects of grommet
insertion on aural fullness in patients with Ménière’s Disease, with the
latest direct evaluation published in 1971. Although there is a theoretical
need for future research to fill this gap in knowledge, in order to
definitively confirm or disprove the efficacy of this intervention on this
often debilitating symptom, the evidence presented does not lend much
weight to its efficacy.
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Tables and Figures
Table I
Summary of studies included in this review.(19-23)
Study Aims of study Methods of study Number of patients
involved
Method of aural
fullness assessment
Time elapsed until aural
fullness measurement
after VT insertion
Changes in aural
fullness
Dayal (1971)
Observations on the use of
grommets in Meniere's
disease. (19)
Observing the effect of
grommet insertion on the
symptoms of patients with
unilateral MD.
Grommets were inserted in the
ears of affected patients.
Change in symptoms was then
recorded during follow-up.
7 Unspecified Varied between 3 months to
1 year. Not specified for each
patient.
Relieved in 6
patients,
unchanged in 1.
Densert et al. (1997)
Immediate effects of middle
ear pressure changes on the
electrocochleographic
recordings in patients with
Meniere's disease: A clinical
placebo-controlled study.
(20)
Placebo-controlled
randomised control study
testing the change in
electrocochleographic
measurements after VT
insertion and then after
exposure to a middle ear
pressure generator/placebo.
Patients meeting study criteria
had a VT inserted into their
tympanic membrane. In most
cases, patients were exposed to
active or placebo treatment a
week later. The active
treatment delivered positive
pressure changes to the ear via
a generator, while the placebo
was a similar looking device
that did not deliver any
pressure pulses.
39 patients overall. 18
were treated with placebo
and hence the VT alone.
Visual scales were used to
measure the subjective
symptom of aural fullness.
Unspecified No significant
changes. Exact
results not shown.
Odkvist et al. (2000)
Effects of middle ear
pressure changes on clinical
symptoms in patients with
Meniere's disease - A clinical
multicentre placebo-
controlled study.
(21)
Placebo-controlled study
testing the effects of middle
ear pressure therapy (via a
Meniett device) on the
clinical symptoms of patients
with Meniere’s disease.
Patients had a VT inserted and
had a clinical and audiological
assessment prior to this and 2
weeks after insertion. Those
who met criteria received two
weeks of pressure/placebo
treatment, at which point the
clinical symptoms and hearing
were evaluated.
56 patients overall. 25
were treated with placebo
and hence the VT alone.
Visual analogue scales
(VAS) questionnaires were
used to measure the
frequency and intensity of
aural fullness. The exact
nature of this VAS is
unknown.
4 weeks No significant
improvement.
Specific results are
unavailable.
Postema et al. (2008)
Intratympanic gentamicin
therapy for control of
vertigo in unilateral
Meniere's disease: a
prospective, double-blind,
randomized, placebo-
controlled trial.
(22)
Double blind placebo-
controlled randomised
control trial comparing the
effects of intratympanic
gentamicin therapy to a
placebo on vertigo in
patients with unilateral MD.
A middle ear VT was inserted in
participants’ affected ears. Four
weeks after this, weekly
gentamicin or placebo was
delivered into the middle ear
through the ventilation tube
weekly for 4 more weeks.
Patient’s symptoms and degree
of hearing loss was measured
at specified points.
28 patients overall. 12
were treated with placebo
and hence the VT alone.
Patients completed a form
rating their aural fullness
as 0 (none), 1 (mild), 2
(moderate) and 3
(severe). This was done
before and at every
follow-up appointment
during therapy.
Results are for 1 year follow-
up. Measurements were also
taken weekly for 4 weeks
following an initial 4 weeks
post-VT insertion, 6 weeks
and 6 months.
Perceived fullness
did not change.
Lall (1969)
Meniere's disease and the
grommet
(a survey of its therapeutic
effects)
(23)
A survey conducted to
understand the therapeutic
effects of grommet insertion
on Meniere’s disease.
Questionnaires were sent to
surgeons who were members of
the British Association of
Otolaryngologists in 1966.
Surgeons replied on the results
of grommet operations carried
out up to the end of 1967.
Specific details about the
individual operations of
participating surgeons were not
available.
147 patients, treated by
36 surgeons.
Survey sent to surgeons
asked about how aural
fullness changed post-
operation. The study
publishes this as
“relieved”, “no change” or
“incomplete data.” It is
unclear how each surgeon
specifically evaluated
patients’ symptoms in this
case.
Varied between 2 and 14
months. Not specified for
each patient.
66% relieved, 22%
no change, 12%
incomplete data.
Table II
Details of patients in included studies.(19-24)
Study Level of
evidence (24)
Total no. of
patients in
study
No. of patients whose
aural fullness was
assessed
Age of patients Gender of
patients
involved
Type of disease
Dayal (1971)
Observations on the use of
grommets in Meniere's
disease.
(19)
Case Series
(Level 4)
7 7 30-55 Male All unilateral MD based
on history, symptoms,
pure tone audiogram,
Fowler’s Recruitment
test and the Caloric
test.
Densert et al. (1997)
Immediate effects of middle
ear pressure changes on the
electrocochleographic
recordings in patients with
Meniere's disease: A clinical
placebo-controlled study.
(20)
Randomised
trial
(Level 2)
39 18 patients were treated
with placebo and hence the
VT alone, although it is
unspecified how many of
these patients actually had
aural fullness.
20-65 Unspecified MD according to 1995
AAOHNS criteria for
duration of at least 1
year but no more than
6 years prior to the
test. Laterality of
disease unspecified.
Odkvist et al. (2000)
Effects of middle ear
pressure changes on clinical
symptoms in patients with
Meniere's disease - A clinical
multicentre placebo-
controlled study.
(21)
Randomised
trial
(Level 2)
56 25 patients received placebo
treatment and hence VT
alone, although it is
unspecified how many of
these patients actually had
aural fullness.
20-65 Unspecified Patients all had definite
MD, though laterality
and diagnostic criteria
are unspecified. All
patients had a 20-65
dB hearing impairment
and active vestibular
symptoms close to the
test.
Postema et al. (2008)
Intratympanic gentamicin
therapy for control of
vertigo in unilateral
Meniere's disease: a
prospective, double-blind,
randomized, placebo-
controlled trial.
(22)
Randomised
trial
(Level 2)
28 12 patients received the
placebo treatment and hence
VT alone. Complete data
could not be acquired for 2
of these patients.
Median ages of 53
and 55 for the
placebo (VT) and
intervention
(gentamicin) groups
respectively.
Unspecified All unilateral MD
according to 1995
AAOHNS criteria.
Lall (1969)
Meniere's disease and the
grommet
(a survey of its therapeutic
effects)
(23)
Case series
(Level 4)
147 129 (Data was available on
88% of the patients)
Unspecified Unspecified 132 patients had MD of
varying severity.
Disease laterality was
unspecified. The other
15 patients were
classified as having
“Meniere syndrome.”
Figure I
Flowchart showing literature searching process for review.
Summary
- Ménière’s disease can present with aural fullness, the mechanisms
of which is not currently understood.
- There is no current consensus on the ideal way of treating aural
fullness in Ménière’s Disease.
- Despite a thorough literature search, only five studies could be
found measuring the effects of transtympanic ventilation tube
insertion on aural fullness in Ménière’s Disease, only two of which
directly measured the effect of the intervention on aural fullness.
- In light of the paucity of evidence, heterogeneity and mixed
findings of available studies, it is our recommendation that future
clinical trials be conducted to determine the place of ventilation tube
insertion in the management of the symptom of aural fullness in
Ménière’s Disease.
- The current evidence does not allow the recommendation of
ventilation tube insertion to treat aural fullness
in Ménière’s Disease.
